Back to Results

Lakefront Biotherapeutics NV (GLPGF)

Lakefront Biotherapeutics NV is a biotechnology company focused on developing medicines in oncology and immunology, with research activities primarily in the United States and Europe. Its pipeline includes GLPG3667, which is being studied in phase 2 trials for dermatomyositis and systemic lupus erythematosus, as well as GLPG5101, a CD19 CAR-T candidate in phase 1/2 testing for relapsed or refractory non-Hodgkin lymphoma. The company is also advancing GLPG5301, a BCMA CAR-T candidate in phase 1/2 development for relapsed or refractory multiple myeloma. Lakefront Biotherapeutics maintains collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is based in Mechelen, Belgium. It was formerly known as Galapagos NV and adopted its current name in May 2026.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-GLPG.F
$29.22
11.3% Upside
Fair
Not available
Not available
Excellent
0.0%
November 12, 2026
2.8x
0.5x
1.7x
1.961 B
-647.6 M
0.4%
36.1%
49.8
-39.0%
Valuation • Fair Value

Lakefront Biotherapeutics NV (OTC-GLPG.F) Fair Value by Valuation Model

Review the available estimates for Lakefront Biotherapeutics NV (OTC-GLPG.F), including DCF Fair Value, Ben Graham Formula Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$29.22

Estimated upside of 11.3% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$28.55

Discounted cash flow valuation reference.

Ben Graham Formula Value

$116.38

Classic Ben Graham valuation formula reference.

Comps Fair Value

$29.55

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 5 available valuation references for Lakefront Biotherapeutics NV (OTC-GLPG.F) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Lakefront Biotherapeutics NV (OTC-GLPG.F)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

1.131 B

Current operating scale indicator.

Revenue Forecast

35.231 M

Forward revenue estimate.

EBITDA

649.7 M

Current operating profitability reference.

EBITDA Forecast

-151.3 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Lakefront Biotherapeutics NV (OTC-GLPG.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Lakefront Biotherapeutics NV (OTC-GLPG.F)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Excellent

Positive financial-health read.

Piotroski Score

7

Relatively strong quality score.

Beneish M-Score

-4.84

No elevated caution signal from this screen.

Altman Z-Score

49.8

Relatively strong balance-sheet zone.

FCF / Net Income

-39.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Lakefront Biotherapeutics NV (OTC-GLPG.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Lakefront Biotherapeutics NV (OTC-GLPG.F)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 12, 2026

Days to Earnings

51

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Lakefront Biotherapeutics NV (OTC-GLPG.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Lakefront Biotherapeutics NV (OTC-GLPG.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Lakefront Biotherapeutics NV (OTC-GLPG.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Lakefront Biotherapeutics NV (OTC-GLPG.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Lakefront Biotherapeutics NV (OTC-GLPG.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Lakefront Biotherapeutics NV (OTC-GLPG.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Lakefront Biotherapeutics NV (OTC-GLPG.F) Stock FAQ

Data-supported answers about Lakefront Biotherapeutics NV (OTC-GLPG.F), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$29.22
Estimated upside 11.3%
Valuation Rating
Undervalued
Estimated upside of 11.3%
Financial Health
Excellent
Current financial-health read

The current fair value estimate for Lakefront Biotherapeutics NV (OTC-GLPG.F) is $29.22. This implies an estimated upside of 11.3% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 11.3% versus the current market price.

The current financial health read for Lakefront Biotherapeutics NV (OTC-GLPG.F) is Excellent. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Lakefront Biotherapeutics NV (OTC-GLPG.F) is November 12, 2026.

The latest available data indicates no current dividend yield for Lakefront Biotherapeutics NV (OTC-GLPG.F).

The current P/E ratio listed for Lakefront Biotherapeutics NV (OTC-GLPG.F) is 2.8x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Lakefront Biotherapeutics NV is 1.961 B.

The current enterprise value listed for Lakefront Biotherapeutics NV is -647.6 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Lakefront Biotherapeutics NV is OTC-GLPG.F, and the stock is listed on OTC Markets.

Lakefront Biotherapeutics NV (OTC-GLPG.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Lakefront Biotherapeutics NV is 0.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Lakefront Biotherapeutics NV is 36.1%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B